Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

Portfolio Update

18 Dec 2018 15:30

RNS Number : 8779K
CATCo Reinsurance Opps Fund Ltd
18 December 2018
 

FOR IMMEDIATE RELEASE

 

18 December 2018

CATCo Reinsurance Opportunities Fund Ltd. (the "Company")

Portfolio Update

 

 

To: SFS, London Stock Exchange and Bermuda Stock Exchange

 

Markel CATCo Investment Management Ltd., as Investment Manager of the Company (the "Manager"), announces its intention to establish specific loss reserves for the 30 November 2018 Net Asset Value (NAV) held by the Company in relation to 2018 major loss events.

 

As previously noted, the Company's Ordinary Shareholders and C Shareholders are exposed to potential losses arising from 2018 major loss events, including Hurricane Florence, Hurricane Michael, Typhoon Jebi, and the California Wildfires (Camp and Woolsey). The Manager has estimated the specific loss reserves required to cover 2018 major events and to be recorded within the 30 November 2018 NAV will be c. 23% for Ordinary Shares and c. 45% for C Shares. Estimated impacts are based on the 31 October NAV (inclusive of the 8 December 2018 announcement of the estimated reduction of the Ordinary Share Side Pocket Investment due to the 2017 specific loss reserve strengthening).

 

Recent insurance market reports have indicated Hurricane Florence is expected to result in industry insured losses at levels that will now exceed levels that would be absorbed by the attritional reserve. In addition, market reports have indicated that Hurricane Michael industry insured losses are also expected to reach or exceed the upper end of preliminary industry insured loss estimates. Therefore, a portion of the 30 November 2018 specific loss reserve will be used to cover potential portfolio exposure for both of these events.

 

Further, preliminary industry insured loss estimates have placed the total industry insured loss for the California Wildfire events, Camp and Woolsey, at c. USD 14 billion. The Manager has assumed that additional loss increases may develop beyond preliminary estimates, as was observed during the 2017 California Wildfire events. Therefore, the Manager has established a preliminary reserve for these events assuming the combined industry insured losses may increase significantly beyond the current reported levels of loss. It is also assumed that losses on Camp and Woolsey will result in material exposure to cedants who have both first and second event coverage for wildfire events.

 

It should be noted that significant levels of uncertainty will remain on 2018 events, especially as it relates to the California Wildfires. Preliminary reserves have been established based on very early information, including catastrophe modeled data, industry insured loss estimates, and early advice from brokers and cedants. Formal loss advices from cedants are not expected to be received on 2018 major events until year-end 2018, or further into 2019. Specific reserves will be re-assessed for sufficiency following the receipt of formal cedant loss reports. Therefore, it is possible that the expected portfolio exposure to 2018 loss events could change, resulting in either an increase or decrease to reserves, after further information has been made available.

 

The Manager expects the 30 November 2018 NAV to be released by 24 December 2018.

 

 

For further information:

Markel CATCo Investment Management Ltd.

 

Judith Wynne

General Counsel

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Chief of Investor Marketing

Telephone: +1 441 493 9001

Email: mark.way@markelcatco.com

Numis Securities Limited

 

David Benda / Hugh Jonathan

Telephone: +44 (0) 20 7260 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PFUBUBDDIDBBGII
Date   Source Headline
29th Mar 201111:40 amRNSIssue of Equity
29th Mar 201111:36 amRNSDirector/PDMR Shareholding
7th Mar 20111:49 pmRNSNet Asset Value(s)
7th Feb 20118:30 amRNSPortfolio Update
7th Feb 20118:11 amRNSNet Asset Value(s)
14th Jan 20117:00 amRNSPortfolio Update
7th Jan 20113:33 pmRNSHolding(s) in Company
23rd Dec 201011:00 amRNSHolding(s) in Company
20th Dec 20107:00 amRNSResult of Placing and Admission to SFM
13th Jul 20064:12 pmRNSHolding(s) in Company
10th Jul 20063:20 pmRNSHolding(s) in Company
7th Jul 20062:51 pmRNSOffer for Cambridge Antibody
3rd Jul 20064:56 pmRNSDirectorate Change
30th Jun 20064:12 pmRNSHolding(s) in Company
30th Jun 20064:06 pmRNSDelisting
30th Jun 200610:27 amRNSAdditional Listing
30th Jun 20067:02 amRNSOffer for Cambridge Antibody
27th Jun 20062:26 pmRNSHolding(s) in Company
27th Jun 200612:34 pmRNSHolding(s) in Company
23rd Jun 20062:25 pmRNSAppointment of Directors
22nd Jun 20063:07 pmRNSRule 8.3- CAT
22nd Jun 200611:31 amRNSCAT Limited appoints new CE
22nd Jun 200611:11 amRNSEPT Disclosure
22nd Jun 200611:09 amRNSEPT Disclosure
22nd Jun 20067:02 amRNSOffer for Cambridge Antibody
21st Jun 20065:11 pmRNSRule 8.1- C.A.T.
21st Jun 200611:30 amRNSEPT Disclosure
21st Jun 200610:20 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
20th Jun 200610:36 amRNSEPT Disclosure
19th Jun 20063:25 pmRNSRule 8.3 - Cambridge Antibody
19th Jun 20061:07 pmRNSRule 8.3- (CAT)
19th Jun 200611:30 amRNSEPT Disclosure
19th Jun 200611:23 amRNSEPT Disclosure
19th Jun 200610:33 amRNSEPT Disclosure
16th Jun 200611:45 amRNSEPT Disclosure
16th Jun 200611:24 amRNSEPT Disclosure
16th Jun 200611:08 amRNSEPT Disclosure
15th Jun 20065:01 pmRNSEPT Disclosure
15th Jun 20062:48 pmRNSRule 8.3- (CAT)
15th Jun 20062:17 pmRNSRule 2.10 Announcement
15th Jun 200612:45 pmRNSEPT Disclosure
15th Jun 200611:36 amRNSEPT Disclosure
14th Jun 20063:38 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20063:05 pmRNSRule 8.3- Cambridge Antibody
14th Jun 20061:43 pmRNSRule 8.3- (CAT)
14th Jun 200611:36 amRNSEPT Disclosure
14th Jun 200611:15 amRNSEPT Disclosure
14th Jun 200610:59 amRNSEPT Disclosure
14th Jun 200610:23 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.